SuperworthMinerva Neurosciences EPS NERV
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$28.87
- Latest quarter, Q2 FY26
- −$0.14
- Fiscal year 2025
- −$26.80
- −14205% on the year before
Minerva Neurosciences' earnings per share was −$28.87 over the twelve months to Jun 30, 2026, down 2051% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.14.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$26.80 | −14205% |
| FY2024 | $0.19 | n/a |
| FY2023 | −$4.65 | n/a |
| FY2022 | −$6.01 | n/a |
| FY2021 | −$9.37 | −2052% |
| FY2020 | $0.48 | n/a |
| FY2019 | −$14.88 | n/a |
| FY2018 | −$10.32 | n/a |
| FY2017 | −$6.80 | n/a |
| FY2016 | −$7.84 | n/a |
| FY2015 | −$9.28 | n/a |
| FY2014 | −$39.28 | n/a |
| FY2013 | −$5.68 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.14 | n/a | −$28.87 | |
| Q1 FY26 | −$2.86 | n/a | −$29.16 | |
| Q4 FY25 | −$25.51 | n/a | −$26.80 | |
| Q3 FY25 | −$0.36 | −112% | −$1.85 | |
| Q2 FY25 | −$0.43 | n/a | $1.48 | |
| Q1 FY25 | −$0.50 | n/a | $0.82 | |
| Q4 FY24 | −$0.56 | n/a | $0.19 | |
| Q3 FY24 | $2.97 | n/a | −$0.44 | |
| Q2 FY24 | −$1.09 | n/a | −$4.44 | |
| Q1 FY24 | −$1.13 | n/a | −$4.47 | |
| Q4 FY23 | −$1.19 | n/a | −$4.65 | |
| Q3 FY23 | −$1.03 | n/a | −$4.72 |
Against its peers
Companies in Drug Manufacturers - General nearest Minerva Neurosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NERVMinerva Neurosciences | −$28.87 | −2051% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Minerva Neurosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.